Clinical trials: Cardiovascular Disease Prevention
Atrial Fibrillation
Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting
- Trial name
- RIVA-F (NCT02690155)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
- Where
- United States
- Volunteers
- 38,831 people
- Sponsor
- Bayer
Atrial Fibrillation, Oral Anticoagulation
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
Patients with atrial fibrillation (AF) who have had a prior stroke are at very high risk of recurrent ischemic stroke. About 40% of these strokes are due to large emboli which result in large cerebral vessel occlusion (LVO).
- Conditions
- Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
- Trial name
- INTERCEPT (NCT05723926)
- Testing
- Vine Filter
- Where
- 21 sites in United States, Brazil and 2 more
- Volunteers
- 2,000 people
- Sponsor
- Javelin Medical
Lipid Metabolism Disorders, Cardiovascular Diseases
Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD
Retrospective observational study of the efficacy and safety of statin monotherapy or statins in combination with ezetimibe in patients receiving lipid-lowering therapy in both primary and secondary prevention of cardiovascular…
- Trial name
- UNISON (NCT04895098)
- Testing
- statin and ezetimibe combination therapy, statin monotherapy
- Where
- 31 sites in Russia
- Volunteers
- 1,000 people
- Sponsor
- Akrikhin
Prevention of Arterial and Venous Thrombosis
A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty.
- Trial name
- NCT06825416
- Testing
- SHR-2004 injection, Enoxaparin sodium injection
- Where
- 2 sites in China
- Volunteers
- 1,165 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Atrial Fibrillation
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
The purpose of the study is to compare the one-year and two-year risk of each of the following individual outcomes: Stroke and systemic embolism (SE), major bleeding and death between new users of anticoagulant for Stroke…
- Trial name
- BROTHER (NCT02864758)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonists, dabigatran (Pradaxa)
- Where
- France
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Thrombosis, Venous
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).
- Trial name
- NCT00320398
- Testing
- Fondaparinux
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Heart Failure - NYHA II - IV
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
This study will compare two different methods to pace the heart to treat heart failure including: 1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left…
- Trial name
- SYNCHRONICITY (NCT07069738)
- Testing
- CRT-D with a Quadripolar LV lead, CRT-D with INGEVITY+ pace/sense lead
- Where
- 42 sites in United States
- Volunteers
- 850 people
- Sponsor
- Boston Scientific Corporation
Sick Sinus Syndrome, Brady-Tachy Syndrome
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
The objective of this trial is to show the therapeutic efficacy of the preventive pacing therapies of the Selection 9000 and Vitatron T70 DR pacemakers, dedicated to handle atrial fibrillation (AF).
- Trial name
- NCT00224341
- Testing
- Pacemaker Vitatron Selection 9000, Pacemaker Vitatron T70
- Where
- 37 sites in France
- Volunteers
- 360 people
- Sponsor
- Vitatron France
Pulmonary Embolism, Deep Vein Thrombosis
SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis
Patients diagnosed with pulmonary embolism (blood clot in the lung) or deep vein thrombosis (blood clot in a leg vein) are at risk for these blood clots to reoccur.
- Trial name
- NCT00071279
- Testing
- SR34006 (idraparinux sodium) Injection
- Where
- 65 sites in United States, Australia and 18 more
- Volunteers
- 1,215 people
- Sponsor
- Sanofi
Hereditary Angioedema (HAE)
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
- Trial name
- NCT02586805
- Testing
- DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk
- Where
- 41 sites in United States, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- Shire
Atrial Fibrillation
Patient Convenience Study
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its…
- Trial name
- NCT02597920
- Where
- 148 sites in Belgium, Denmark and 5 more
- Volunteers
- 1,852 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)
Describe patient and physician assessed factors for patient well-being when treated with Pradaxa for stroke and embolism prevention in atrial fibrillation either compared to previous antithrombotic treatment (switcher)
- Trial name
- NCT02839746
- Where
- Spain
- Volunteers
- 671 people
- Sponsor
- Boehringer Ingelheim
Hereditary Angioedema (HAE)
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
Primary Objective - To assess the relative efficacy of two dose levels of CINRYZE (500 Units and 1000 Units) administered by intravenous (IV) injection every 3 or 4 days to prevent angioedema attacks in children 6 to 11 years of…
- Trial name
- NCT02052141
- Testing
- CINRYZE 500, CINRYZE 1000
- Where
- 8 sites in United States, Germany and 3 more
- Volunteers
- 12 people
- Sponsor
- Shire
Deep Vein Thrombosis, Post-thrombotic Syndrome
Elastic Compression Stockings for Prevention of Post-thrombotic Syndrome
Post thrombotic syndrome (PTS) is a frequent and burdensome complication of proximal deep-vein thrombosis.Therapeutic options for PTS are limited and mainly rely on its prevention.
- Trial name
- CELEST (NCT01578122)
- Testing
- 25mmHg ECS, 35 mmHg ECS
- Where
- 57 sites in France
- Volunteers
- 350 people
- Sponsor
- Laboratoires Innothera
Hereditary Angioedema Types I and II
A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
The aim of this study is to assess the long-term safety of C1-esterase inhibitor (C1-INH) in preventing hereditary angioedema (HAE) attacks when it is administered under the skin of subjects with HAE.
- Trial name
- NCT02316353
- Testing
- C1-esterase inhibitor
- Where
- 32 sites in United States, Australia and 9 more
- Volunteers
- 126 people
- Sponsor
- CSL Behring
Venous Thromboembolism
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
Primary objective: To demonstrate the superiority of extended VTE prophylaxis with enoxaparin 40mg sc qd for 28 ± 4 days, compared to placebo, both following 10 ± 4 days of initial treatment with enoxaparin 40mg sc qd Secondary…
- Trial name
- NCT00077753
- Testing
- enoxaparin sodium
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 4,726 people
- Sponsor
- Sanofi
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
- Trial name
- ROXI-INCLINE (NCT07430956)
- Testing
- REGN7508, REGN9933
- Where
- 44 sites in United States, Canada
- Volunteers
- 2,628 people
- Sponsor
- Regeneron Pharmaceuticals
Vascular Ehlers-Danlos Syndrome
Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.
The purpose of this study is to investigate the efficacy of enzastaurin compared to placebo in preventing arterial events (rupture, dissection, pseudoaneurysm, carotid-cavernous sinus fistula, or aneurysm, fatal or not) leading…
- Trial name
- PREVEnt (NCT05463679)
- Testing
- Enzastaurin
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Aytu BioPharma, Inc.
Cerebral Infarction
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)
Sarpogrelate (MCI-9042) is an antiplatelet drug that decreases 5-hydroxytryptamine (5-HT) levels in platelets via a blockade of 5-HT2 receptors; it has been used in atherosclerotic peripheral arterial disease.
- Trial name
- NCT00129805
- Testing
- MCI-9042, Aspirin
- Volunteers
- 1,510 people
- Sponsor
- Tanabe Pharma Corporation
Lower Leg Wound
A Pilot Study of the WoundWand™ Debridement Device on Infection Prevention
A Pilot Study of the WoundWand™ Debridement Device on Infection Prevention
- Trial name
- WoundWand (NCT01924806)
- Testing
- WoundWand™ Debridement Device, Standard of Care sharp debridement
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 11 people
- Sponsor
- Smith & Nephew, Inc.